NUMERAL LIMITED - Update on Healthcare and Biotech Strategy, Investments and the Finalisation of Audited Results

Update on Healthcare and Biotech Strategy, Investments and the Finalisation of Audited Results

NUMERAL LTD
(Incorporated in the Republic of Mauritius)
(Registration number: 098177 C1/GBL)
Primary Listing SEM share code: NXII.N0000.
Secondary Listing JSE share code: XII
ISIN: MU0330N00004
("the Company" or "the Group" or "Numeral")

UPDATE ON HEALTHCARE AND BIOTECH STRATEGY, INVESTMENTS AND THE FINALISATION OF AUDITED
RESULTS

Shareholders are provided with the following updates as follows:

Update on healthcare and biotech segment:

1. The Board is pleased to announce that Numeral has expanded its healthcare and biotechnology
   strategy through a number of strategic initiatives across the premium wellness, sports recovery and
   healthcare sectors.

   During the period, the Group launched Boost & Recovery, a premium longevity, sports wellness
   and recovery concept designed to deliver science-backed recovery, performance optimisation
   and preventative healthcare services.

   The first flagship facility is currently under development at Kyalami, with completion expected
   within the next 60 days. Additional flagship locations are planned for Sandton City and Camps Bay,
   forming part of a broader national rollout strategy.

   Each centre will offer an integrated range of advanced recovery and longevity treatments,
   including whole-body cryotherapy, hyperbaric oxygen therapy, HOCATT ozone therapy, red light
   therapy, clinical diagnostics and other evidence-based recovery technologies designed to
   optimise health, wellness and athletic performance.

2. The Board is further pleased to announce that Numeral has made its first strategic investment into
   WestMed, an established healthcare platform based in Stellenbosch in the Western Cape.

   WestMed operates primary healthcare clinics, specialist medical practices, aesthetic medicine,
   advanced surgical services and regenerative medicine capabilities. The investment aligns with
   Numeral's long-term strategy of building a leading healthcare, health technology and
   biotechnology platform.

   Further details regarding this investment will be announced in due course.


3. The Board has decided to exit its investments in Longevity and Isopharm due to the inability to
   secure timely operational and financial information from the founder for purposes of consolidation.
   The Board has thus determined that it does not have control as envisaged in IFRS 10, nor significant
   influence in terms of IAS 28, and has accounted for the two companies as investments in its results
   for the year ended 28 February 2026.

   Management decided to enter into a settlement agreement with the founder subsequent to year
   end to recover its investments as opposed to forcing operational control on the founder and
   potentially destroying the underlying businesses. This fact has been disclosed in the Annual
   Financial Statements for February 2026.

4. The shareholding in Cryo-Save was increased to 51% during the year ended 28 February 2026 as
   expected. Cryo-Save contrinues to operate well and is enjoying solid growth, being a cornerstone
   of the biotech business.

Update on finalisation of Annual Financial Statements for the year ended 28 February 2026:
The audited results are targeted to be finalised on or about 15 July 2026. The accounting treatment of
the two investments in Longevity and Isopharm has been one of the major delaying factors.

Following the decision to exit the investments at cost as detailed above, the accounting treatment
can be finalised and the audit for the year ended 28 February 2026 completed.

Numeral has its primary listing on the Stock Exchange Mauritius and a secondary listing on the AltX of
the JSE.

By Order of the Board
9 July 2026

Executive Directors:                                                 Non-Executive Directors:
Dave van Niekerk                                                      Mohamed Yusuf Sooklall
Neville Graham                                                         Dr Aansa Devi Bedacee
Jacobus Botma                                                                    Kevin Evans

JSE Sponsor:                                        Management Company and Company Secretary:
AcaciaCap Advisors Proprietary Limited                       LTS Management Services Limited

Date: 09-07-2026 02:04:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.